Mesothelioma

Mesothelioma - What It Is, What Causes It, and What You Can Do About It

Mesothelioma is a rare and aggressive cancer that forms in the mesothelium, a thin protective membrane that lines the chest cavity, abdominal organs, heart, and testes. The mesothelium produces a small amount of lubricating fluid that allows these organs to move smoothly against each other during breathing, digestion, and other normal functions. When cancer develops in this tissue, it disrupts organ function and spreads along the membrane surfaces in patterns that make it difficult to treat with standard approaches.

There are different types of mesothelioma depending on where the tumors form, but they all share one overwhelming cause: exposure to asbestos.

Asbestos fibers are microscopic, sharp, and nearly indestructible. When inhaled or swallowed, they can become lodged in the mesothelium, where they remain for the rest of a person's life. Over time, those fibers trigger chronic inflammation, cellular damage, and the accumulation of genetic mutations that eventually produce cancer. The entire process from first exposure to mesothelioma diagnosis typically spans 20 to 50 years or more. That's why mesothelioma is being diagnosed today in people whose exposure happened decades ago on job sites that no longer exist, with products that have long since been discontinued, made by companies that declared bankruptcy decades ago.

Mesothelioma was virtually nonexistent before asbestos was widely used in American industry. In a review of 2,276 consecutive autopsies performed at New York's Mount Sinai Hospital between 1883 and 1910 (before commercial asbestos use took off) not a single case of mesothelioma was identified. The disease simply did not exist in the population because the population was not being exposed to asbestos. That changed dramatically in the twentieth century, as asbestos was added to thousands of products and millions of workers were exposed without warning. As journalist Paul Brodeur documented in 1968: asbestos had become "practically ubiquitous in modern society," present in every automobile, airplane, ship, factory, home, and farm across the country.

Today, approximately 3,000 to 4,000 Americans are diagnosed with mesothelioma each year, and that number has remained largely stable for decades despite reduced asbestos use. The long latency period means the consequences of mid-twentieth-century exposure are still arriving.

Mesothelioma is not a random disease caused by genetics, lifestyle, or bad luck. It is overwhelmingly the result of asbestos exposure.

Types of Mesothelioma by Location

Mesothelioma is classified first by where in the body it develops. The location determines the symptoms a patient experiences, the diagnostic process, the treatment options available, and the expected prognosis. Each type is named for the specific mesothelial membrane where the cancer originates.

Pleural Mesothelioma (Lining of the Lungs)

Pleural mesothelioma is the most common form, accounting for 75 to 90% of all mesothelioma diagnoses. It develops in the pleura, the two-layered membrane that surrounds the lungs and lines the inside of the chest wall. This is the type most directly tied to inhaled asbestos fibers, which lodge in the pleural tissue after penetrating the deep lung. Patients typically present with shortness of breath, chest pain, persistent cough, and pleural effusion. A pleural effusion is a buildup of fluid between the pleural layers and is often the first sign something is wrong. Treatment options include surgery, chemotherapy, immunotherapy with checkpoint inhibitors (now FDA-approved for unresectable pleural mesothelioma), and radiation, often in combination. Median survival varies widely by stage and treatment approach.

Read the full guide to pleural mesothelioma: causes, diagnosis, and what you need to know

Pleural mesothelioma: diagnosis, treatment, and prognosis in 2026

Peritoneal Mesothelioma (Lining of the Abdomen)

Peritoneal mesothelioma accounts for roughly 10 to 20% of cases and develops in the peritoneum, the membrane lining the abdominal cavity and covering the surfaces of abdominal organs. Asbestos fibers reach the peritoneum through lymphatic transport from the lungs, through ingestion and gastrointestinal transit, or — only in women — through perineal migration of asbestos-contaminated talc via the reproductive tract. Patients typically present with abdominal pain, bloating, ascites (fluid buildup in the abdomen), and unexplained weight loss. The development of cytoreductive surgery combined with heated intraperitoneal chemotherapy (CRS-HIPEC) has transformed outcomes for eligible patients, with median survival at experienced centers now exceeding three years and some patients living five to ten years or more after treatment.

Read the full guide to peritoneal mesothelioma: causes, diagnosis, and what you need to know

Peritoneal mesothelioma in women: diagnosis, exposure, and legal options

Peritoneal mesothelioma treatment, costs, and prognosis in 2026

Pericardial Mesothelioma (Lining of the Heart)

Pericardial mesothelioma is extremely rare, accounting for less than 1% of all mesothelioma cases. It develops in the pericardium, the membrane surrounding the heart. Because of its location, it is often diagnosed late (sometimes only at autopsy) and produces symptoms that overlap with common cardiac conditions: chest pain, irregular heartbeat, pericardial effusion (fluid around the heart), and progressive shortness of breath. Treatment options are limited by the anatomical constraints of operating near the heart, and the approach is typically palliative, focused on managing symptoms and controlling fluid buildup. When surgery is feasible, it may involve removal of the pericardium (pericardiectomy) combined with systemic therapy.

Read the full guide to pericardial mesothelioma: diagnosis, treatment, and prognosis in 2026

Testicular Mesothelioma (Lining of the Testicles)

Testicular mesothelioma is also extremely rare, accounting for fewer than 1% of all cases. It develops in the tunica vaginalis, a mesothelial membrane that surrounds each testicle and that forms during embryonic development as a direct extension of the peritoneum. Most patients present with painless scrotal swelling or a hydrocele (fluid around the testicle) that is initially assumed to be benign. The cancer is frequently discovered only during or after surgery for what was thought to be a routine condition. A 2025 study from Memorial Sloan Kettering Cancer Center is the largest single-institution series ever published on this disease and it found that an aggressive, multidisciplinary treatment approach produced a median overall survival of 4.5 years, substantially better than the two-year median reported in earlier literature.

Read the full guide to testicular mesothelioma: diagnosis, treatment, and prognosis in 2026

Regardless of where it starts, the cause of mesothelioma is nearly always the same: asbestos fibers that reached the mesothelium through inhalation, ingestion, or internal transport.

Types of Mesothelioma by Cell Type

In addition to location, mesothelioma is classified by its histological subtype, which refers to the type of cells that make up the tumor. This classification is determined through microscopic examination of tissue obtained by biopsy, and it is one of the most consequential pieces of information in a patient's diagnosis. Cell type influences how fast the cancer grows, how it responds to treatment, what clinical trials a patient may be eligible for, and what survival outcomes are realistically expected.

Epithelioid Mesothelioma

Epithelioid mesothelioma is the most common subtype, accounting for approximately 50 to 70% of all diagnosed cases. It is characterized by relatively uniform, organized cells that tend to grow in structured patterns. This organized growth makes epithelioid mesothelioma more responsive to surgery, chemotherapy, and immunotherapy than other subtypes, and patients with epithelioid histology generally have the most favorable prognosis.

Learn more about epithelioid mesothelioma

Sarcomatoid Mesothelioma

Sarcomatoid mesothelioma accounts for approximately 10 to 20% of cases and is the most aggressive subtype. Its spindle-shaped, disorganized cells spread rapidly and resist most standard treatments, including surgery and chemotherapy. Patients with sarcomatoid histology face the shortest median survival of any mesothelioma subtype, and the limited treatment options available underscore the critical importance of early and accurate pathological diagnosis.

Learn more about sarcomatoid mesothelioma

Biphasic (Mixed) Mesothelioma

Biphasic mesothelioma contains both epithelioid and sarcomatoid cells within the same tumor and accounts for approximately 20 to 30% of cases. Its behavior and prognosis depend on which cell type predominates. A tumor that is 80% epithelioid will behave very differently from one that is 80% sarcomatoid, even though both carry the same biphasic label. Accurate quantification of the epithelioid-to-sarcomatoid ratio is essential for treatment planning.

Learn more about biphasic mesothelioma

If you or a loved one has been diagnosed with mesothelioma, ask your doctor whether the histological subtype has been determined. It affects treatment planning, prognosis, clinical trial eligibility, and in some cases the way damages are calculated in asbestos legal claims. If the pathology report is unclear or the subtype has not been specified, request clarification or a second opinion from a pathologist with mesothelioma experience.

What Causes Mesothelioma

Mesothelioma is one of the rarest cancers in the world, yet it has one of the clearest and most thoroughly documented causes of any human malignancy. The causal link between asbestos and mesothelioma is not a matter of scientific debate. It is the settled consensus of every major public health, regulatory, and research organization in the world:

The World Health Organization (WHO) states unequivocally that "all forms of asbestos, including chrysotile, are carcinogenic to humans" and estimates that occupational asbestos exposure causes more than 200,000 deaths per year worldwide.

The National Cancer Institute (NCI) confirms that asbestos has been classified as a known human carcinogen by the U.S. Department of Health and Human Services, the Environmental Protection Agency, and the International Agency for Research on Cancer — and that "it is thought that most mesotheliomas are due to asbestos exposure."

The Agency for Toxic Substances and Disease Registry (ATSDR), a division of the Centers for Disease Control and Prevention, states that "all forms of asbestos are hazardous, and all can cause cancer."

The National Institute for Occupational Safety and Health (NIOSH) has issued formal intelligence bulletins documenting the carcinogenicity of asbestos in occupational settings and recommending that workplace exposures be reduced to the lowest feasible concentration.

The U.S. Environmental Protection Agency (EPA) determined in 2020 that chrysotile asbestos poses unreasonable risks to human health and finalized a rule in March 2024 banning ongoing uses of chrysotile asbestos in the United States. The agency cited the need to "protect people from lung cancer, mesothelioma, ovarian cancer, laryngeal cancer and other health problems caused by asbestos exposure."

The Occupational Safety and Health Administration (OSHA) regulates asbestos as a known workplace carcinogen, setting permissible exposure limits and requiring employers to monitor, control, and remediate asbestos hazards across all industries where exposure occurs.

There is no established safe level of exposure to asbestos. There is no threshold below which asbestos contact is harmless. In epidemiology, mesothelioma is considered a signal tumor for asbestos exposure: the disease signals that a person was exposed to asbestos.

The Discovery That Changed Everything

The causal link between asbestos and mesothelioma was not always known. Before 1960, mesothelioma was considered an extremely rare tumor, so uncommon that it was barely recognized in medical literature. The breakthrough came in 1960, when South African pathologist Dr. J.C. Wagner published a landmark study in the British Journal of Industrial Medicine documenting an epidemic of mesothelioma among residents of the Cape Province, near crocidolite (blue asbestos) mines.

Wagner's study analyzed 33 cases of pleural mesothelioma — a remarkable number of cases of what had previously been an almost unknown disease. What made Wagner's findings extraordinary was not just the number of cases but who was getting sick. Only 8 of the 33 patients had evidence of occupational exposure to asbestos, while 20 of the remaining 25 had lived near the mines as infants. Many of those diagnosed had never worked directly with asbestos but were family members, neighbors, and children of asbestos workers.

Wagner demonstrated that 32 of the 33 patients had some form of contact with asbestos, establishing strong circumstantial evidence for the causal relationship. For the first time, scientists recognized that brief, low-level, non-occupational contact with asbestos could cause a fatal cancer. Wagner's study revealed that mesothelioma was both an occupational hazard for asbestos workers and a community-wide health threat to those who lived near asbestos facilities.

Wagner's study ignited a wave of international research. Within a few years, physicians at Mount Sinai Hospital in New York and medical centers across Europe were documenting the disease in insulation workers, shipyard laborers, and factory hands. They also found the disease in wives and children of asbestos workers who had never set foot in a workplace but had been exposed to fibers carried home on clothing, skin, and hair. The global medical consensus began to take shape: asbestos exposure caused mesothelioma, and no amount of exposure was safe.

What the Asbestos Industry Knew — and When They Knew It

The medical community's understanding of asbestos and mesothelioma was built through rigorous, independent research. The asbestos industry's understanding was built through something very different: their own internal studies, conducted decades earlier, that they systematically suppressed.

As early as the 1930s, asbestos manufacturers had medical evidence that their products were causing fatal lung disease. By the 1940s and 1950s, they understood the connection between asbestos and cancer. But rather than warn their workers or the public, they made a calculated business decision to conceal the evidence. They classified internal studies. They pressured researchers to alter findings. And they funded public relations campaigns emphasizing the "safety" of asbestos products while workers were dying.

They got away with it for decades because the disease didn't appear until 20 to 50 years after exposure. By the time workers started getting diagnosed, the connection to their exposure was obscured by the passage of time. The companies that had exposed them had moved on to new products, new markets, and new workers.

It took a dying insulation worker from Texas to change that. In 1973, Clarence Borel became the first person in American history to win a lawsuit proving that asbestos had caused his mesothelioma and that the companies who manufactured the products he used were legally responsible. Borel filed his case because he knew the evidence in his lawsuit could expose the cover-up and protect others who were still being exposed. He was right. The Borel decision opened the floodgates of litigation that eventually forced the asbestos industry's internal documents into the public record. And that finally revealed a decades-long corporate conspiracy that had knowingly traded human lives for profit.

Every legal option available to mesothelioma patients today exists because of what Clarence Borel started.

Read the full story of Clarence Borel

The Latency Period of Mesothelioma

One of the defining characteristics of mesothelioma is the extraordinary length of time between first asbestos exposure and the development of symptoms. In most cases, the latency period is 20 to 50 years, though cases with latency exceeding 60 or even 70 years have been documented. This means a construction worker exposed to asbestos insulation in 1970 might not develop symptoms until 2020 or later. A Navy veteran who served on asbestos-insulated ships in the 1960s might not be diagnosed until he is in his seventies or eighties.

The latency period explains why mesothelioma incidence has remained stable at approximately 3,000 to 4,000 new cases per year in the United States despite significantly reduced asbestos use since the 1980s. The exposures that are producing today's diagnoses happened decades ago, and the pipeline of latent disease will continue to generate new cases for years to come. It also explains why asbestos companies were able to conceal the danger for so long.

Other Rare Causes of Mesothelioma

Asbestos causes the overwhelming majority of mesothelioma cases, but a small number of cases involve other contributing factors:

Genetic susceptibility. Mutations in the BAP1 gene can predispose individuals to mesothelioma by impairing the body's ability to repair DNA damage. Families with inherited BAP1 mutations have elevated rates of mesothelioma and certain other cancers. However, a BAP1 mutation alone is almost never sufficient to cause mesothelioma. In nearly every documented case, asbestos exposure triggered the disease. The genetic vulnerability explains why some individuals develop mesothelioma after relatively modest exposure while others with heavier exposure do not, but the asbestos remains the proximate cause. Even people who are genetically more susceptible to mesothelioma can seek compensation when asbestos exposure triggers the disease. That principle is taught to first-year law students as the eggshell skull doctrine: if your negligence causes an injury in a person whose skull is unusually fragile, the person's fragility is not a defense. Put another way: "You broke it, you bought it." Companies that exposed a genetically vulnerable person to asbestos are fully liable for the resulting cancer. The victim's predisposition does not reduce their responsibility — it simply explains why the damage their negligence caused was so severe.

Therapeutic radiation. High-dose radiation therapy delivered to the chest or abdomen for treatment of other cancers (such as Hodgkin's lymphoma) has been identified as an independent cause of mesothelioma in a small number of cases. Radiation-induced mesothelioma tends to have a shorter latency period than asbestos-related disease, and it develops in the radiation field rather than following the anatomical distribution associated with fiber exposure.

Childhood mesothelioma. In rare cases, children develop mesothelioma without a clear exposure history. Some of these cases are associated with BAP1 or other inherited mutations. Others remain unexplained, and illustrate the genuine gaps in scientific understanding that the research community continues to investigate.

Idiopathic mesothelioma. "Idiopathic" is the medical term for a disease with no identified cause. A small percentage of mesothelioma cases are classified as idiopathic because no asbestos exposure history can be documented. But that label deserves scrutiny, because the absence of a documented exposure is not the same as the absence of an actual exposure. Self-reporting of asbestos contact is notoriously unreliable. In one study, researchers used analytical transmission electron microscopy to examine lung tissue from mesothelioma patients who reported no history of asbestos exposure — and found that 61% of patients had in fact been exposed to large quantities of asbestos. They simply didn't know they had been exposed.

Many cases labeled "idiopathic" are almost certainly cases in which a more thorough investigation would reveal the exposure that caused the disease. And critically, if asbestos exposure of any kind is eventually identified, the case is no longer idiopathic by definition. Because there is no safe level of asbestos exposure, any confirmed contact is sufficient to establish causation. A mesothelioma that develops in a person who was exposed to asbestos is an asbestos-caused mesothelioma — regardless of how brief or seemingly minor the exposure was.

Debunking the SV40 Theory of Mesothelioma Causation

Simian Virus 40 (SV40), a monkey virus that contaminated early polio vaccines administered between 1955 and 1963, was once proposed as a potential cause of mesothelioma. Early laboratory studies showed SV40 could transform human cells in vitro, and some researchers reported detecting traces of the virus in mesothelioma tumor samples, leading to speculation that the contaminated vaccines might have contributed to mesothelioma risk in people who received them.

That theory has not held up. Multiple large-scale epidemiological studies comparing cancer rates in people who received SV40-contaminated vaccines against those who received uncontaminated vaccines found no increased risk of mesothelioma or any other cancer in the contaminated group. Further investigation revealed that many of the original positive detections of SV40 in tumor samples were attributable to laboratory contamination and flawed testing methodology, not to genuine viral presence in human tissue. The medical consensus today is unambiguous: SV40 is not a credible cause of mesothelioma.

The theory is worth mentioning here because, despite being scientifically discredited, some defense attorneys still raise SV40 in asbestos litigation in an effort to suggest that their client's product was not the cause of a plaintiff's cancer. It is the same strategy the asbestos industry has always used: introduce doubt where the science is clear, and hope that complexity creates confusion. The epidemiological evidence does not support it.

If someone has mesothelioma and a history of asbestos exposure — even 50 or more years ago — asbestos is almost certainly the cause. That is the settled consensus of the international medical community.

How Mesothelioma Is Diagnosed

Mesothelioma can be difficult to diagnose, particularly in its early stages, because its symptoms overlap with far more common conditions. Pleural mesothelioma mimics pneumonia, COPD, and lung cancer. Peritoneal mesothelioma is mistaken for irritable bowel syndrome, ovarian cancer, or liver disease. Pericardial mesothelioma resembles congestive heart failure. And testicular mesothelioma is almost always treated as a benign hydrocele before the cancer is discovered. The result is that many patients experience months of evaluation for the wrong condition before the correct diagnosis is reached.

Accurate diagnosis requires a combination of imaging, fluid testing, tissue biopsy, and specialized pathological analysis. Each of these steps plays a different role, and for most patients, tissue biopsy is the only way to reach a definitive diagnosis.

Diagnostic Imaging

Diagnosis often begins with imaging ordered to investigate unexplained symptoms. A contrast-enhanced CT scan is the standard first-line study for both pleural and peritoneal mesothelioma, capable of identifying pleural thickening, effusions, peritoneal nodules, ascites, and suspicious masses. CT provides a preliminary picture of disease extent but cannot confirm the diagnosis on its own. That's because the findings it produces that are consistent with mesothelioma are also consistent with other conditions.

PET-CT combines anatomical and metabolic imaging to identify areas of active tumor growth and can detect metastatic disease that CT alone may miss. MRI provides superior soft-tissue detail and is particularly valuable for evaluating tumor invasion into the diaphragm, chest wall, or bowel surfaces. Ultrasound is often used to guide diagnostic procedures such as thoracentesis or paracentesis and, in testicular mesothelioma, is typically the first imaging study performed to evaluate scrotal swelling.

No combination of imaging studies can definitively diagnose mesothelioma. Imaging identifies where to look for tissue to biopsy, but the biopsy is what confirms the diagnosis.

Fluid Testing

In many mesothelioma cases, fluid collects in the body cavity where the tumor is growing: pleural effusion in the chest, ascites in the abdomen, pericardial effusion around the heart, or hydrocele fluid around the testicle. Draining this fluid through thoracentesis, paracentesis, pericardiocentesis, or aspiration serves both therapeutic and diagnostic purposes because it relieves symptoms and provides a sample that can be examined for cancer cells.

However, fluid cytology detects mesothelioma in fewer than 30% of cases. The malignant cells present in fluid are often difficult to distinguish from benign reactive mesothelial cells and from the cells of other cancers. Fluid analysis is useful as a preliminary step but is almost never sufficient to confirm a mesothelioma diagnosis.

Biopsy: The Gold Standard for Mesothelioma Diagnosis

A tissue biopsy is required for a definitive mesothelioma diagnosis. The specific approach depends on the type and location of disease.

For pleural mesothelioma, video-assisted thoracoscopic surgery (VATS) is the preferred method, allowing the surgeon to directly visualize the pleural cavity, obtain multiple tissue samples, and in some cases perform therapeutic procedures during the same session. VATS provides diagnostic sensitivity approaching 95% or higher. For peritoneal mesothelioma, diagnostic laparoscopy serves a dual function: it confirms the diagnosis through targeted biopsies and simultaneously assesses the Peritoneal Cancer Index, which determines surgical candidacy for CRS-HIPEC. CT-guided needle biopsy is an alternative when minimally invasive surgery is not feasible, though it yields smaller samples that may limit the pathologist's ability to determine the histological subtype. For testicular mesothelioma, diagnosis is typically made on the tissue obtained during orchiectomy.

Pathology and Immunohistochemistry

Once tissue is obtained, a pathologist examines it under a microscope and performs immunohistochemical (IHC) staining to confirm the diagnosis and distinguish mesothelioma from other cancers that can mimic it. Mesothelioma tumors are typically positive for calretinin, WT-1, cytokeratin 5/6, and D2-40 (markers of mesothelial origin) and negative for CEA, MOC-31, BerEP4, and TTF-1 (markers associated with adenocarcinomas and other tumors). This staining panel is what separates a confirmed mesothelioma diagnosis from a suspected one.

The pathology report will also identify the histological subtype as epithelioid, sarcomatoid, or biphasic, which is essential for every subsequent treatment decision.

If there is any uncertainty about the diagnosis, request a second opinion from a pathologist with mesothelioma experience. Misdiagnosis has real consequences: different cancers require different treatments, and a patient treated for the wrong disease is losing time they cannot afford to lose. Second-opinion pathology review is standard practice for rare cancers and your medical team should support it.

For detailed diagnostic information specific to each type, see our disease-specific pages on pleural, peritoneal, pericardial, and testicular mesothelioma.

Treatment Overview

Treatment for mesothelioma depends on where the cancer is located, how far it has spread, the histological subtype, and the patient's overall health. In most cases, the best outcomes come from multimodal therapy, meaning a combination of surgery, chemotherapy, and immunotherapy tailored to the individual patient by a team with mesothelioma experience. While mesothelioma is rarely curable in the traditional sense, modern treatment strategies are extending survival, reducing symptoms, and improving quality of life in ways that were not possible even a decade ago.

The single most consistent finding across the mesothelioma treatment literature is this: where you are treated determines your treatment outcome. Outcomes at high-volume specialized centers consistently and measurably outperform those at community hospitals treating the same disease. This has been documented directly in peritoneal mesothelioma, where treatment at an academic center doubles the median survival time, and the same pattern holds across all forms of the disease. The rarity of mesothelioma means that the institutional experience, surgical volume, multidisciplinary tumor boards, and clinical trial access that drive better outcomes are concentrated at a small number of centers.

Pleural Mesothelioma

Treatment for pleural mesothelioma may include pleurectomy/decortication (P/D) or extrapleural pneumonectomy (EPP). Both are surgical approaches that remove the diseased pleural tissue, with EPP also removing the lung on the affected side. First-line chemotherapy is typically cisplatin or carboplatin combined with pemetrexed. The FDA approval of nivolumab plus ipilimumab (checkpoint inhibitors) for unresectable pleural mesothelioma marked a landmark advance in systemic treatment, and multiple clinical trials are currently evaluating additional immunotherapy combinations, targeted therapies, and novel drug delivery methods.

Pleural mesothelioma: treatment options and prognosis in 2026

Peritoneal Mesothelioma

For eligible patients, the standard treatment is cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). That's a procedure that surgically removes all visible tumor from the abdominal cavity and then bathes the peritoneal surfaces with heated chemotherapy delivered directly to the site of disease. CRS-HIPEC has transformed outcomes in peritoneal mesothelioma, extending median survival from approximately one year to three years or more at experienced centers, with some patients surviving five to ten years after treatment. Eligibility depends on factors including tumor burden (assessed by the Peritoneal Cancer Index), histological subtype, and overall fitness. Patients who are not candidates for CRS-HIPEC may receive systemic chemotherapy, immunotherapy, or emerging combination regimens.

Peritoneal mesothelioma: treatment, costs, and prognosis in 2026

Pericardial Mesothelioma

Pericardial mesothelioma is typically diagnosed late, and treatment is most often palliative, focused on managing symptoms such as chest pain and pericardial effusion rather than attempting cure. When surgery is feasible, pericardiectomy (removal of the pericardium) may be combined with systemic chemotherapy. The rarity of this disease means that treatment approaches are based on case reports and small series rather than controlled studies.

Learn more about pericardial mesothelioma

Testicular Mesothelioma

Radical inguinal orchiectomy is the standard first-line surgical treatment for testicular mesothelioma. Increasingly, aggressive approaches that include hemiscrototomy and retroperitoneal lymph node dissection (RPLND) are being used at specialized centers. The 2025 Memorial Sloan Kettering series demonstrated that a multimodal protocol combining aggressive surgery with selective systemic therapy produced a median survival of 4.5 years — roughly double the historical two-year benchmark. Chemotherapy is extrapolated from pleural mesothelioma protocols, and immunotherapy with checkpoint inhibitors is emerging as an option for recurrent or metastatic disease.

Testicular mesothelioma: diagnosis, treatment, and prognosis in 2026

Getting the Best Care Takes Resources

The treatments described above are expensive, and the best of them often require traveling to a specialized center that may be hundreds of miles from home. Surgery, chemotherapy, immunotherapy, extended hospital stays, post-surgical care, imaging, surveillance, lost wages, and the indirect costs of a serious illness accumulate rapidly. Insurance rarely covers everything, and the gap between what is covered and what is needed can be the difference between accessing the best available care and settling for whatever is available locally.

That gap is precisely what asbestos compensation is designed to close. Trust fund claims, personal injury lawsuits, VA benefits, and disability programs exist specifically to give mesothelioma patients the financial resources to pursue the treatment that gives them the best chance. You're not limited to the treatment that your insurance dictates or that your savings can cover.

Getting Treatment and Financial Help for Mesothelioma

Legal Options for Mesothelioma Patients and Families

Every legal right available to mesothelioma patients today exists because of one man: Clarence Borel, a Texas insulation worker who was dying of mesothelioma and who chose to spend what remained of his life fighting to protect the coworkers he knew were still being exposed to asbestos.

Borel didn't want to sue, and he wasn't looking for a payout. He agreed to go forward with his case only when he understood that the evidence produced in litigation could expose what the asbestos companies had been hiding and protect the men he had worked alongside for decades. In 1973, he became the first person in American history to prove in court that asbestos had caused his cancer and that the companies who manufactured the products he used were legally responsible. He won. And then the floodgates opened.

The thousands of cases that followed Borel's forced the asbestos industry's internal documents into the public record, including memos, suppressed medical studies, and correspondence between executives who knew their products were killing people. The bankruptcies that resulted from that litigation produced the asbestos trust funds. The trust funds created a system that, for all its imperfections, can move quickly enough to help people whose time is measured in months and years rather than decades. Every trust fund, every legal precedent, and every compensation mechanism available to mesothelioma patients today traces directly back to what Clarence Borel started.

If you have mesothelioma, you may be entitled to compensation from multiple sources, and in many cases, these sources can be pursued simultaneously.

Asbestos Trust Fund Claims

When major asbestos manufacturers faced overwhelming litigation, many filed for bankruptcy. Courts required them to establish asbestos compensation trusts, which are dedicated funds set aside to pay current and future victims. More than 60 of these trusts exist today, collectively holding billions of dollars, and they continue to accept and pay claims. Trust fund claims are paper-based, require no courtroom appearance, and are expedited for mesothelioma patients. Most patients qualify for claims against multiple trusts, because most workers encountered asbestos products from more than one manufacturer over the course of a career. Our firm maintains a proprietary database of more than 200,000 verified asbestos exposure sites across the United States, cross-referenced with the products used at each site and the trusts established by their manufacturers.

Learn more about asbestos trust fund claims

Mesothelioma Lawsuits

When the company responsible for your exposure is still operating and has not established a trust, a personal injury lawsuit may be the appropriate path. Lawsuits against solvent defendants can result in compensation substantially exceeding trust fund payments, and most mesothelioma cases settle before trial. For families who have lost someone to mesothelioma, wrongful death claims follow the same framework and can be filed by surviving spouses, children, or dependents. Acting early strengthens the case: it preserves the ability to provide a deposition, which is among the most powerful evidence in any asbestos claim.

Learn more about mesothelioma lawsuits

VA Benefits for Veterans

Veterans are disproportionately represented among mesothelioma patients because the United States military used asbestos extensively in ships, barracks, vehicles, aircraft, and nearly every type of military infrastructure. Navy veterans who served on asbestos-insulated ships are especially affected. If you served and have been diagnosed with mesothelioma, you may be entitled to VA disability compensation and full VA healthcare coverage. Mesothelioma disability ratings are typically 100%, qualifying veterans for the maximum compensation rate. VA benefits can be pursued alongside trust fund claims and lawsuits without affecting eligibility for either — they are entirely separate systems with separate funding.

Learn more about VA benefits for mesothelioma

Social Security Disability (SSDI)

Mesothelioma is included in the Social Security Administration's Compassionate Allowances program, which fast-tracks disability benefit approval. If you have worked enough quarters to qualify, benefits can be approved in weeks rather than months, and approval also accelerates Medicare eligibility. That's important when treatment costs are mounting and insurance gaps are growing.

Learn more about SSDI for mesothelioma

Statute of Limitations: Why Timing Matters

Every state sets a filing deadline for mesothelioma claims, typically beginning from the date of diagnosis rather than the date of exposure. But these deadlines are real, and in some states they arrive faster than people expect. A consultation with an experienced asbestos attorney costs nothing, obligates you to nothing, and takes less time than most medical appointments. The information it produces is useful immediately, regardless of when or whether you decide to proceed.

Why Legal Action Belongs on a Medical Page

Compensation from asbestos claims is what allows patients to say yes to the best available treatment instead of asking what insurance will cover. It funds travel to a specialized cancer center when the nearest one is hundreds of miles away. It pays for the immunotherapy session insurance denied, the home health aide who makes recovery possible, the out-of-pocket costs that accumulate around a serious illness. It replaces income that stopped when treatment made working impossible. And it holds accountable the companies that made a calculated decision to prioritize profit over human life.

That is why pursuing legal options and pursuing the best available treatment are not separate projects. They are the same project.

Getting Treatment and Financial Help for Mesothelioma

How We Can Help Your Family

A mesothelioma diagnosis affects everything, including your health, your finances, and your family's future. We understand that because we've lived it. Our founding attorney lost multiple family members to asbestos-related cancers. That experience shaped how this firm operates: we treat every client as if they were family, because we understand what this diagnosis means in a way that extends beyond the legal file.

The Law Offices of Justinian C. Lane, Esq. – PLLC has recovered more than $400 million for asbestos victims since 2014. We represent mesothelioma patients and their families nationwide, with offices in Texas, Arizona, California, and Washington. We work on a contingency fee basis with no upfront costs and no fees unless we recover compensation for you. We handle the evidence, the filings, the trust claims, the negotiations, and the deadlines. You focus on your health and your family.

We can help you understand where and how you were exposed to asbestos (even if the exposure happened decades ago) using our proprietary database of more than 200,000 verified exposure sites and millions of pages of medical studies, company records, and court documents. We can help you file trust fund claims and lawsuits simultaneously, pursue VA benefits and SSDI if applicable, and connect you with top mesothelioma treatment centers and medical travel support.

Call us today at 833-4-ASBESTOS (833-427-2378) or schedule your free consultation online. No cost. No pressure. No obligation.

You didn't choose this diagnosis. But you can choose what happens next, and you don't have to face it alone. We're here to help you fight back, secure the care you deserve, and hold accountable the companies that put you in this position.

References

1. Strauchen, J. (2011). Rarity of malignant mesothelioma prior to the widespread commercial introduction of asbestos: the Mount Sinai autopsy experience 1883–1910. American Journal of Industrial Medicine, 54(6), 467–469.

2. Enewold, L., Sharon, E., & Thomas, A. (2017). Patterns of care and survival among patients with malignant mesothelioma in the United States. Lung Cancer, 112, 102–108. https://doi.org/10.1016/j.lungcan.2017.08.009

3. Naso, J.R., Levine, A.B., Farahani, H., et al. (2021). Deep-learning based classification distinguishes sarcomatoid malignant mesotheliomas from benign spindle cell mesothelial proliferations. Modern Pathology, 34, 2028–2035. https://doi.org/10.1038/s41379-021-00850-6

4. Dacic, S., Le, S.N., Husain, A., et al. (2020). Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas. Modern Pathology, 33(2), 255–262.

5. Brodeur, P. (1968, October 12). The magic mineral. The New Yorker, 117–165.

6. Wagner, J.C., Sleggs, C.A., & Marchand, P. (1960). Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. British Journal of Industrial Medicine, 17(4), 260–271. https://doi.org/10.1136/oem.17.4.260

7. Strickler, H.D., Goedert, J.J., Devesa, S.S., et al. (1998). Trends in U.S. pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovirus vaccines. Journal of the National Cancer Institute, 90(19), 1458–1461. https://doi.org/10.1093/jnci/90.19.1458

8. Butel, J.S. (2000). Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcinogenesis, 21(3), 405–426. https://doi.org/10.1093/carcin/21.3.405

9. World Health Organization. (2024, September 27). Asbestos: Key facts. https://www.who.int/news-room/fact-sheets/detail/asbestos

10. National Cancer Institute. Asbestos exposure and cancer risk fact sheet. https://www.cancer.gov/about-cancer/causes-prevention/risk/substances/asbestos/asbestos-fact-sheet

11. Agency for Toxic Substances and Disease Registry (ATSDR), Centers for Disease Control and Prevention. Public health statement for asbestos. https://wwwn.cdc.gov/TSP/PHS/PHS.aspx?phsid=28&toxid=4

12. National Institute for Occupational Safety and Health (NIOSH). (2011). Current intelligence bulletin 62: Asbestos fibers and other elongate mineral particles: State of the science and roadmap for research. DHHS (NIOSH) Publication No. 2011-159. https://www.cdc.gov/niosh/docs/2011-159/pdfs/2011-159.pdf

13. U.S. Environmental Protection Agency. EPA actions to protect the public from exposure to asbestos. https://www.epa.gov/asbestos/epa-actions-protect-public-exposure-asbestos

14. Occupational Safety and Health Administration (OSHA). Asbestos. https://www.osha.gov/asbestos

15. Carbone, M., Ly, B.H., Dodson, R.F., et al. (2012). Malignant mesothelioma: Facts, myths, and hypotheses. Journal of Cellular Physiology, 227(1), 44–58. https://doi.org/10.1002/jcp.22724